C.M. Bidwell & Associates’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-478
| Closed | -$147K | – | 496 |
|
|
2025
Q1 | $147K | Sell |
478
-950
| -67% | -$326K | 0.09% | 143 |
|
|
2024
Q4 | $504K | Sell |
1,428
-9
| -0.6% | -$3.31K | 0.31% | 63 |
|
|
2024
Q3 | $515K | Sell |
1,437
-156
| -10% | -$52.7K | 0.31% | 60 |
|
|
2024
Q2 | $507K | Buy |
1,593
+68
| +4% | +$18K | 0.34% | 56 |
|
|
2024
Q1 | $350K | Buy |
1,525
+1,120
| +277% | +$253K | 0.24% | 75 |
|
|
2023
Q4 | $89.1K | Buy |
405
+2
| +0.5% | +$461 | 0.07% | 173 |
|
|
2023
Q3 | $91K | Buy |
+403
| New | +$92.8K | 0.07% | 247 |
|
|
2023
Q1 | – | Sell |
-421
| Closed | -$117K | – | 565 |
|
|
2022
Q4 | $117K | Buy |
+421
| New | +$106K | 0.09% | 200 |
|
|
2022
Q3 | – | Sell |
-250
| Closed | -$59K | – | 548 |
|
|
2022
Q2 | $59K | Hold |
250
| – | – | 0.05% | 265 |
|
|
2022
Q1 | $45K | Sell |
250
-229
| -48% | -$43.6K | 0.03% | 294 |
|
|
2021
Q4 | $104K | Buy |
479
+274
| +134% | +$53.8K | 0.06% | 239 |
|
|
2021
Q3 | $38K | Buy |
+205
| New | +$40.4K | 0.03% | 328 |
|
|
2020
Q3 | – | Sell |
-527
| Closed | -$64K | – | 517 |
|
|
2020
Q2 | $64K | Buy |
+527
| New | +$59.3K | 0.06% | 240 |
|
|
2020
Q1 | – | Sell |
-780
| Closed | -$69K | – | 464 |
|
|
2019
Q4 | $69K | Sell |
780
-130
| -14% | -$11.4K | 0.06% | 199 |
|
|
2019
Q3 | $73K | Buy |
+910
| New | +$73.3K | 0.07% | 211 |
|
|
2019
Q2 | – | Sell |
-4,000
| Closed | -$469K | – | 461 |
|
|
2019
Q1 | $469K | Buy |
4,000
+1,800
| +82% | +$210K | 0.47% | 57 |
|
|
2018
Q4 | $240K | Buy |
+2,200
| New | +$255K | 0.26% | 102 |
|
|
2016
Q2 | – | Sell |
-22,210
| Closed | -$2.48M | – | 321 |
|
|
2016
Q1 | $2.48M | Sell |
22,210
-1,265
| -5% | -$160K | 0.62% | 84 |
|
|
2015
Q4 | $3.68M | Buy |
+23,475
| New | +$3.42M | 0.87% | 56 |
|
|
2015
Q2 | – | Sell |
-1,855
| Closed | -$320K | – | 256 |
|
|
2015
Q1 | $320K | Sell |
1,855
-28,780
| -94% | -$4.39M | 0.07% | 123 |
|
|
2014
Q4 | $3.97M | Sell |
30,635
-45
| -0.1% | -$5.8K | 0.91% | 51 |
|
|
2014
Q3 | $3.95M | Buy |
+30,680
| New | +$3.16M | 0.93% | 50 |
|
|
2014
Q2 | – | Sell |
-3,680
| Closed | -$346K | – | 289 |
|
|
2014
Q1 | $346K | Buy |
3,680
+465
| +14% | +$47.6K | 0.08% | 103 |
|
|
2013
Q4 | $364K | Sell |
3,215
-315
| -9% | -$28.4K | 0.09% | 107 |
|
|
2013
Q3 | $278K | Hold |
3,530
| – | – | 0.08% | 116 |
|
|
2013
Q2 | $232K | Buy |
+3,530
| New | +$227K | 0.07% | 109 |
|
Other funds holding UTHR
ACA
C.M. Bidwell & Associates's UTHR Position: Q2 2025 in Review
C.M. Bidwell & Associates sold out of United Therapeutics (UTHR) in Q2 2025, closing a stake of 478 shares — an estimated $147K sold.
C.M. Bidwell & Associates first reported a position in UTHR in Q2 2013 and held it in 26 quarters. The position peaked at $3.97M in Q4 2014. 670 funds tracked by Wall St. Rank hold UTHR as of Q2 2025.
- C.M. Bidwell & Associates reported no remaining United Therapeutics position as of Q2 2025 after selling out during the quarter.
- C.M. Bidwell & Associates sold 478 United Therapeutics shares in Q2 2025, an estimated $147K.
- C.M. Bidwell & Associates first reported a position in United Therapeutics in Q2 2013 and held it in 26 quarters.
- C.M. Bidwell & Associates's United Therapeutics position peaked at $3.97M in Q4 2014.
- 670 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2025.
Based on C.M. Bidwell & Associates's 13F filing for Q2 2025, filed 14 Aug 2025.